Cargando…

MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma

Long-term survival in oesophageal squamous cell carcinoma (ESCC) is related with pathological response after neoadjuvant chemoradiotherapy (NCRT) followed by surgery. However, effective biomarkers to predict the pathologic response are still lacking. Therefore, a systematic analysis focusing on gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Qiyu, He, Wenwu, Mao, Tianqin, Leng, Xuefeng, Wu, Hong, Li, Wen, Deng, Xuyang, Zhao, Tingci, Shi, Ming, Xu, Chuan, Han, Yongtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514954/ https://www.ncbi.nlm.nih.gov/pubmed/34660277 http://dx.doi.org/10.3389/fonc.2021.711642

Ejemplares similares

Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy
por: He, Wenwu, et al.
Publicado: (2021)

The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a propensity score-matched analysis
por: Deng, Xuyang, et al.
Publicado: (2021)

Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy
por: Zhou, Yehan, et al.
Publicado: (2023)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
por: He, Wenwu, et al.
Publicado: (2022)

Oesophageal squamous cell carcinoma: histogram-derived ADC parameters are not predictive of tumour response to chemoradiotherapy
por: Kozumi, Maiko, et al.
Publicado: (2018)

Mms1 and Mms22 stabilize the replisome during replication stress
por: Vaisica, Jessica A., et al.
Publicado: (2011)

Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)
por: Shang, Xiaobin, et al.
Publicado: (2022)

Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy
por: Yang, Yang, et al.
Publicado: (2020)

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by radical surgery for locally advanced oesophageal squamous cell carcinoma: meta-analysis
por: Kamarajah, Sivesh K, et al.
Publicado: (2022)

The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer
por: Liu, Yiqiang, et al.
Publicado: (2021)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: Hagens, E. R. C., et al.
Publicado: (2020)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Gu, Yi-Min, et al.
Publicado: (2022)

Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma
por: Petrillo, A., et al.
Publicado: (2022)

Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial
por: Nilsson, Magnus, et al.
Publicado: (2022)

Prediction of Locoregional Recurrence-Free Survival of Oesophageal Squamous Cell Carcinoma After Chemoradiotherapy Based on an Enhanced CT-Based Radiomics Model
por: Kong, Jie, et al.
Publicado: (2021)

Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients Treated with Definitive Chemoradiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma
por: Zhang, Guojun, et al.
Publicado: (2023)

The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy
por: Zhou, Jin, et al.
Publicado: (2022)

Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison
por: Eyck, Ben M, et al.
Publicado: (2022)

Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
por: Li, Yue, et al.
Publicado: (2021)

Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy
por: Yoshikawa, R, et al.
Publicado: (2008)

Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer
por: Vollenbrock, S. E., et al.
Publicado: (2019)

Prognostic significance and postoperative chemoradiotherapy guiding value of mean platelet volume for locally advanced esophageal squamous cell carcinoma patients
por: Zhang, Wei, et al.
Publicado: (2023)

Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
por: Ji, Wenbing, et al.
Publicado: (2021)

Prediction of pathological response grading for esophageal squamous carcinoma after neoadjuvant chemoradiotherapy based on MRI imaging using PDX
por: Shi, Jingzhen, et al.
Publicado: (2023)

Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
por: Liu, Yun, et al.
Publicado: (2022)

Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma
por: Duque-Santana, Victor, et al.
Publicado: (2022)

Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon
por: Valkema, Maria J, et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2022)

Predictive Value of Endoscopic Observations and Biopsy After Neoadjuvant Chemoradiotherapy in Assessing the Pathologic Complete Response of Patients With Esophageal Squamous Cell Carcinoma
por: Taghizadeh Kermani, Ali, et al.
Publicado: (2022)

Nomogram constructed by immunological and inflammatory indicators for predicting prognosis of patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy plus surgery
por: Luo, Yun, et al.
Publicado: (2022)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Rad51 Expression Is a Useful Predictive Factor for the Efficacy of Neoadjuvant Chemoradiotherapy in Squamous Cell Carcinoma of the Esophagus
por: Nakanoko, Tomonori, et al.
Publicado: (2013)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies
por: de Klerk, Leonie K., et al.
Publicado: (2021)

A nomogram prediction model for lymph node metastasis risk after neoadjuvant chemoradiotherapy in rectal cancer patients based on SEER database
por: Liu, Xiaoshuang, et al.
Publicado: (2023)

Transcriptional factor regulation network and competitive endogenous RNA (ceRNA) network determining response of esophageal squamous cell carcinomas to neoadjuvant chemoradiotherapy
por: Shao, Mingrui, et al.
Publicado: (2019)

The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review
por: Han, Dan, et al.
Publicado: (2022)

Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysis
por: Luo, Wenhao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p6it5ii68esg70hvjfq2jvi8uj